The addition of angiotensin receptor blockers to angiotensin-converting enzyme inhibitors--what has time told us?

被引：1
作者：
Fabi M.R. [1 ]
Teerlink J.R. [1 ]
机构：
[1] San Francisco VA Medical Center, 4150 Clement Street, San Francisco, 94121, CA
来源：
Current Heart Failure Reports | 2005年 / 2卷 / 2期
关键词：
Captopril; Enalapril; Losartan; Valsartan; Candesartan;
D O I：
10.1007/s11897-005-0010-6
中图分类号：
学科分类号：
摘要：
The neurohormonal hypothesis for the pathogenesis of heart failure found an early champion in the angiotensin-converting enzyme (ACE) inhibitors. More recently, the beta-blockers and aldosterone receptor antagonists have provided significant support by demonstrating marked additive clinical benefit. Within this context, angiotensin receptor blockers (ARBs) were specifically designed to antagonize one of the most potent contributors to the development and progression of heart failure, angiotensin. This review discusses the recent evidence for the addition of ARBs to standard therapy with ACE inhibitors and suggests how this evidence may be used to care for patients.
引用
收藏
页码：59 / 64
页数：5
相关论文
共 93 条
  • [1] Siragy HM(2005)Angiotensin subtype-2 receptors inhibit renin biosynthesis and angiotensin II formation Hypertension 45 133-137
  • [2] Xue C(2004)Cardiovascular and renal function of angiotensin II type-2 receptors Cardiovasc Res 62 460-467
  • [3] Abadir P(1995)The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors Ann Thorac Surg 60 789-792
  • [4] Carey RM(2004)ACE inhibition and bradykinin-mediated renal vascular responses: EDHF involvement Hypertension 43 533-535
  • [5] Johren O(2004)Bradykinin contributes to the systemic hemodynamic effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure Arterioscler Thromb Vasc Biol 24 1043-1048
  • [6] Dendorfer A(1993)Changes in ventricular volume, wall thickness and wall stress during progression of left ventricular dysfunction. The SOLVD Investigators J Am Coll Cardiol 22 43A-48A
  • [7] Dominiak P(2000)Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure Eur Heart J 21 53-57
  • [8] Hartman JC(1990)Identification of a highly specific chymase as the major angiotensin II-forming enzyme in the human heart J Biol Chem 265 22348-22357
  • [9] Imig JD(1995)Discovery of losartan, the first angiotensin II receptor antagonist J Hum Hypertens 9 S3-S18
  • [10] Cruden NL(2001)Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure Circulation 103 148-154
12345678910